Allarity Therapeutics Inc. - ALLR Net earnings per one share for the last twelve months

Allarity Therapeutics protects its business through proprietary biomarker analysis algorithms. The historical EPS YoY TTM trend on the GURU.Markets chart shows that the figure stands at 38.70. Allarity Therapeutics attracts bioinformatics experts via a DNA-based therapy selection IT platform. However, the lack of stable profit sources makes the company's financial condition entirely dependent on the inflow of external investments.
Financial and market metric breakdowns for Allarity Therapeutics, Inc. (ALLR)

Allarity Therapeutics' struggle for survival in the personalized oncology segment amid a capital shortage makes the analysis of business efficiency critical. The 12-month earnings per share trend, which reached 38.70, allows investors to filter out market noise and assess the actual expansion of operational scale, making the relative YoY (ttm) EPS change a key filter against overpaying for the asset.